


Kent Imaging Inc. Receives FDA 510(k) Clearance on SnapshotNIR V3.0 (KD204)

Advanced near infrared spectroscopy imaging for instant and noninvasive tissue oxygen assessment

CALGARY, AB, CANADA, January 6, 2021

[/EINPresswire.com/](https://www.einpresswire.com/) -- [Kent Imaging](https://www.kentimaging.com/) announced today the FDA 510(k) clearance for [SnapshotNIR](https://www.kentimaging.com/) V3.0 (KD204) – now available for shipping. This upgrade provides significant feature enhancements to the imaging technology that advances tissue assessment in acute and chronic wounds. The multitude of advancements include the ability to image most skin tones (overcoming the melanin barrier), linear and surface area wound measurements, easy report generation with image comparisons, and enhanced patient file management, to name a few.



SnapshotNIR displaying captured clinical and tissue oxygenation images in comparison view.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO₂), which is a key indicator of tissue health. Ideal for microcirculation assessment, it conveys a comprehensive picture of the healing capacity of wounds or surgical tissue. This critical information is used to support clinical judgement in choosing, evaluating, and tracking treatment and surgical options throughout the care continuum.

“We are excited to release this enhanced version of SnapshotNIR as part of Kent’s dedication to bringing innovation to this critical market. Robust features asked for by front-line wound care specialists and reconstructive surgeons have been incorporated, delivering a product that can easily track and document wound healing progress and support therapeutic decisions,” noted Pierre Lemire, CEO.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging,



SnapshotNIR V3.0 continues to support the goal of delivering on solutions that aid wound care and surgical specialists in improving patient outcomes and reducing complications.”

Pierre Lemire, CEO

who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

Sandra Jenks

Kent Imaging Inc.

+1 403-455-7610

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/534119391>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.